Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab
Bevacizumab (Bev) is a humanized vascular endothelial growth factor monoclonal antibody that is used with chemotherapeutic drugs for the treatment of metastatic colorectal cancer (mCRC). Bev-induced hypertension (HT) is the most common adverse reaction during clinical practice. However, at present,...
Main Authors: | Tianshu Ren, Hui Jia, Qiong Wu, Yan Zhang, Qun Ma, Dong Yao, Xudong Gao, Danni Xie, Zihua Xu, Qingchun Zhao, Yingshi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.829059/full |
Similar Items
-
Medicinal chemistry of the renin-angiotensin system /
by: Timmermans, P. B. M. W. M., et al.
Published: (1994) -
Regulation of Male Fertility by the Renin-Angiotensin System
by: Marta Gianzo, et al.
Published: (2020-10-01) -
Capacities of laboratory diagnosis in the assessment of the activity of the renin-angiotensin-aldosterone system
by: M L Maksimov
Published: (2010-06-01) -
RENIN-ANGIOTENSIN SYSTEM IN REGULATION OF HEMATOPOIESIS
by: M. L. Kanaeva, et al.
Published: (2018-02-01) -
The clinical relevance of local renin angiotensin systems
by: Duncan John Campbell
Published: (2014-07-01)